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Dermatological toxicities represent the most frequent 
immune-related adverse events (irAEs) induced by 
immune checkpoint inhibitors (1, 2). Safety profiles 
for anti-CTLA-4 inhibitors (ipilimumab) and agents 
targeting the programmed cell death (PD-1) receptor 
(nivolumab, pembrolizumab) appear to be very similar, 
yet a lower frequency is observed with the latter (2). A 
non-specific maculopapular rash represents the most 
frequent cutaneous toxicity of anti-PD-1 inhibitors, with 
a calculated all-grade incidence of 14.3% and 16.7% for 
nivolumab and pembrolizumab, respectively (3). These 
lesions mostly remain mild/moderate, self-limiting, and 
manageable with topical and/or oral steroids. Other 
dermatological complications can also occur, including 
pruritus, xerosis, alopecia, mucosal involvement, autoim-
mune disorders and vitiligo, the latter being exclusively 
described in patients treated for melanoma (1–3). More 
recently, additional skin adverse events have been descri-
bed, including lichenoid reactions, blistering disorders or 
occurrence and exacerbation of psoriasis (1–4). We report 
here 6 patients who developed a mid-facial rash sugges-
tive of papulopustular rosacea, triggered or exacerbated 
by nivolumab therapy, which has not been reported so 
far in association with anti-PD-1 therapy.
CASE REPORTS
All patients (5 men, 1 woman) were treated for different 
types of metastatic solid cancers (Table I). Lesions oc-
curred after 1–19 cycles of nivolumab therapy (3 mg/
kg every 2 weeks). They were mostly localized on the 
medial part of the face, with a characteristic combina-
tion of papules and pustules on an underlying erythema, 
consistent with papulopustular rosacea. Symptoms were 
of mild intensity in all cases (grade 1 papulopustular 
rash) (Fig. 1a) except for one patient, who presented 
with an intolerable grade 2 toxicity (Fig. 1b). Lesions 
were easily managed with symptomatic treatment (to-
pical metrodinazole and/or oral doxycycline), leading 
to a significant improvement in all cases. Nivolumab 
therapy was delayed in one patient and resumed after one 
cycle. Cutaneous biopsy was performed on the patient 
with grade 2 toxicity, which demonstrated characteristic 
histopathological features of papulopustular rosacea, 
with a predominant perivascular and perifollicular CD3+ 
T-cell infiltrate, associated with small and superficial di-
lated blood vessels. In addition, PD-L1 immunostaining 
revealed a strong positivity in the perifollicular infiltrate 
cells (60%) (Fig. 2). Close examination of the patients’ 
history suggested pre-existing erythematotelangiectatic 
rosacea in 3 patients.
DISCUSSION
Development or exacerbation of papulopustular ro-
sacea with anti-PD-1 therapy has not been described 
previously. We cannot, however, rule out the possibility 
that this event is under-reported during its development 
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Table I. Clinical description of reported patients
Case No./
Sex/Age, 
years
Underlying 
malignancies Treatment
Time to 
onset
Clinical 
gradinga Management Outcome
Pre-existing 
rosaceab
1/F/48 Melanoma Nivolumab 19 cycles Grade 1 Topical metronidazole Regression No
2/M/83 Renal cell carcinoma Nivolumab 1 cycle Grade 1 Topical metronidazole Regression Yes
3/M/68 Tonsillar carcinoma Nivolumab 4 cycles Grade 1 Topical metronidazole Regression No
4/M/70 Lung cancer Nivolumab 16 cycles Grade 2 
(intolerable)
Temporary discontinuation, topical 
metronidazole, oral doxycycline 
(100 mg/day)
Regression Yes
5/M/58 Renal cell carcinoma 2 cycles of 
nivolumab+ipilimumab, 
followed by nivolumab 
in monotherapy
8 cycles Grade 1 Topical metronidazole Complete resolutionc Yes
6/M/66 Melanoma 4 cycles of 
nivolumab+ipilimumab, 
followed by nivolumab 
in monotherapy
15 cycles Grade 1 Topical metronidazole, oral 
doxycycline (100 mg/day)
Complete resolutionc No
aFollowing National Cancer Institute CTCae V4.02. berythemato-telangiectatic rosacea. c4 and 8 weeks after the last dose of nivolumab, respectively.
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because of unperformed complete skin examination 
by investigators. Moreover, acneiform rash has been 
infrequently reported with anti-PD-1 agents, but only 
by non-dermatologist investigators (5). This so-called 
“acneiform” rash could potentially correspond, at least 
in part, to a papulopustular rosacea. The pathophysio-
logy of rosacea remains poorly understood, involving 
complex dysregulation of the innate immune, vascular 
and nervous systems (6). However, it has been postulated 
that the adaptive immune system, involving CD4+ Th1/
Th17 cell activities, plays a significant role in the deve-
lopment of all subtypes of rosacea (6, 7). In addition, it 
has been demonstrated that blockade of the PD-1 receptor 
may promote Th1/Th17 pathways (8). We therefore can 
speculate that anti-PD-1 monoclonal antibodies may 
favour the development of either psoriasis (4) or rosacea 
in predisposed patients. Clinicians should be aware of 
this new dermatological adverse event, which remains, in 
our experience, self-limiting, but may lead to temporary 
interruption. Early recognition and appropriate manage-
ment also appear crucial to prevent a negative impact on 
patients’ quality of life.
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Fig. 2. PD-L1 immunostaining individualizing a strong positivity in 
the lympho-histiocytic infiltrate, associated with exocytosis into 
the pilosebaceous follicle (×50 magnification Ventana Ultraview DAB 
Detection Kit; Antigen retrieval was a standard automated process on 
the Ventana BenchMark XT clone SP142, Spring Bioscience, Pleasanton, 
CA, USA). 
Fig. 1. Clinical examples of nivolumab-
induced rosacea. (a) Grade 1 papulopustular 
rosacea in case 2 and (b) intolerable grade 2 
papulopustular rosacea in case 4 induced by 
nivolumab therapy.
